Amphion Innovations PLC Partner Company releases positive clinical results
October 05 2017 - 2:00AM
RNS Non-Regulatory
TIDMAMP
Amphion Innovations PLC
05 October 2017
Amphion Innovations plc
("Amphion" or "the Company")
Amphion Partner Company, Motif Bio, Announces Positive Topline
Results for iclaprim in the REVIVE-2 Phase 3 Study
-- Iclaprim met the primary endpoint
-- Iclaprim was well tolerated in the study
-- NDA submission expected in the first quarter of 2018
Amphion Innovations plc (AIM: AMP), the developer of medical,
life science, and technology businesses, comments on Partner
Company Motif Bio plc ("Motif", AIM: MTFB, NASDAQ: MTFB) following
positive topline results from its REVIVE-2 trial, a global Phase 3
clinical trial evaluating Motif's lead investigational drug
candidate iclaprim in patients with acute bacterial skin and skin
structure infections (ABSSSI), as announced 4 October 2017.
Amphion owns 14.1% of Motif Bio's issued share capital.
Richard Morgan, CEO of Amphion Innovations commented: "We are
pleased that Motif Bio's lead antibiotic, iclaprim, has now
successfully completed both of its Phase III trials. Yesterday,
Motif Bio announced the topline data for REVIVE-2, the second of
the two trials, which showed that iclaprim achieved the primary
endpoint of non-inferiority compared to vancomycin, the current
standard of care, at the early time point (ETP), and also achieved
non-inferiority at the test of cure endpoint, 7 to 14 days after
study drug discontinuation. Combined with the positive topline data
for REVIVE-1, as announced 18 April 2017, Motif Bio is on track to
submit a New Drug Application to the US FDA for iclaprim in the
first quarter of 2018. Amphion owns 14.1% of Motif Bio, and we
continue to believe that Motif Bio is not fully valued compared to
other comparable antibiotic companies at the same stage of
development."
For further information please contact:
Amphion Innovations Tel: +1 (212) 210 6224
Charlie Morgan
Walbrook PR Tel: +44 (0)20 7933 8780
or
Mike Wort/ Paul McManus amphion@walbrookpr.com
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and
technology businesses.
We use our extensive experience in company building to invest
and build shareholder value in high growth companies in the US and
UK. Amphion has significant shareholding in 7 Partner Companies
developing proven technologies targeting substantial commercial
marketplaces. The Amphion model has been refined to optimise the
commercialisation of patents and other intellectual property within
the Partner Companies. The Partner Companies collectively own or
control over 200 separately identified pieces of intellectual
property, a number which grows rapidly each year.
On the web: www.amphionplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAXELEDLXFFF
(END) Dow Jones Newswires
October 05, 2017 02:00 ET (06:00 GMT)
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Apr 2023 to Apr 2024